ClinicalTrials.Veeva

Menu

Finding and Treating Unsuspected and Resistant TB to Reduce Hospital Transmission (FAST)

Mass General Brigham logo

Mass General Brigham

Status

Unknown

Conditions

Tuberculosis

Treatments

Other: FAST

Study type

Interventional

Funder types

Other

Identifiers

NCT02355223
2014P002396

Details and patient eligibility

About

The study is designed to evaluate the clinical impact of a novel strategy for tuberculosis (TB) infection control known as FAST (Find cases Actively based on cough surveillance, Separate temporarily, and Treat effectively). It is anticipated that this will decrease time to effective treatment initiation and also decrease transmission of TB to health care workers.

Full description

There is longstanding evidence that tuberculosis (TB) transmission is not from TB patients on effective treatment, but from unsuspected cases, and cases with unsuspected drug resistance. This study seeks to investigate the implementation of a refocused TB transmission control approach that we call FAST (Find cases Actively based on cough surveillance, Separate temporarily, and Treat effectively based on molecular drug-susceptibility testing [DST]). We will conduct this study at Hospital Nacional Hipólito Unanue in Lima, Peru. Our hypothesis is that FAST will reduce delays in identifying infectious TB patients (and unsuspected drug resistance) entering the hospital, facilitate timely effective therapy, and thereby reduce the risk of TB transmission in a cost-effective manner. We will assess the impact of FAST on TB transmission by evaluating IGRA conversions among health care workers at the intervention site, Hospital Nacional Hipolito Unanue (HNHU), and two control sites, Hosptial Nacional Arzobispo Loayza (HNAL) and Hospital Nacional Sergio Bernales (HNSB). We will also evaluate acceptability and barriers to/facilitators of FAST, novel screening strategies, and health care worker IGRA testing using a mixed methods approach.

Enrollment

11,060 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria (for patients):

  • adult (≥ 18 years) patients who are receiving care in the emergency department or being admitted for inpatient care from any other hospital area
  • patient presenting with cough or TB risk factors of prior or current TB diagnosis and/or contact of an individual with TB
  • able to participate by providing a sputum sample and/or exhaled breath test sample

Exclusion Criteria (for patients):

  • no specific exclusion criteria at initial screening if the patient meets the above inclusion criteria.

Inclusion Criteria (for health care workers):

  • being an employee or intern at Hospital Nacional Hipolito Unanue (HNHU), Hospital Nacional Arzobispo Loayza (HNAL) or Hospital Nacional Sergio Bernales (HNSB) and deemed to be at risk of exposure to tuberculosis based on line of work
  • age ≥ 18 years
  • willing and able to provide informed consent for participation

Exclusion Criteria (for health care workers):

  • no specific exclusion criteria

Trial design

Primary purpose

Health Services Research

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

11,060 participants in 1 patient group

FAST Implementation
Other group
Description:
This single center study will consist of introducing a TB screening program called FAST (Find cases Actively, Separate safely, and Treat Effectively) within the hospital among patients presenting for care who have cough or TB risk factors, and testing them for tuberculosis using a combination of rapid screening and diagnostics tools. The study will evaluate the process of implementation as well as the impact on reducing tuberculosis transmission to health care workers over successive years.
Treatment:
Other: FAST

Trial contacts and locations

1

Loading...

Central trial contact

Edward Nardell, MD; Dylan Tierney, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems